UPDATE 1-Arca reaches agreement with FDA on heart-drug study

* To do study in 3200 heart patients with specific genotype

* Sees starting the trial in H2 2011

* Shares up as much as 32 pct

May 17 (BestGrowthStock) – Arca Biopharma Inc (ABIO.O: ) said it
reached an agreement with the U.S. health regulator on the
design of a trial to test its experimental treatment for heart
failure, sending its shares soaring 32 percent.

According to a special protocol assessment agreement, the
drug, bucindolol, will be evaluated in a trial that plans to
enroll 3,200 patients with chronic heart failure who have the
specific genotype that appears to respond most favorably to the
drug.

The special protocol assessment provides a company with a
written agreement that the design and analysis of the trial are
adequate to support a marketing application submission with the
U.S. health regulator.

The main goal of the planned trial, which will compare
bucindolol with an approved heart-failure drug, metoprolol
CR/XL, is to look at a composite of cardiovascular mortality
and cardiovascular hospitalization.

Arca, which received a complete response letter from the
U.S. Food and Drug Administration in June 2009 saying a
late-stage trial of the drug did not adequately demonstrate its
efficacy, expects to begin the proposed trial in the second
half of 2011.

Shares of the company were up 27 percent to $5.42 in
morning trade on Nasdaq. They reached a high of $5.63 earlier
in the session.

Stock Market Tarding

(Reporting by Esha Dey in Bangalore; Editing by Prem
Udayabhanu)

UPDATE 1-Arca reaches agreement with FDA on heart-drug study